Home National PLI Push Lifts Pharma, Bulk-Drug Manufacturing

PLI Push Lifts Pharma, Bulk-Drug Manufacturing

0
1

HYDERABAD: Production linked incentive (PLI) schemes were delivering substantial gains in pharmaceutical manufacturing, investment and employment, although progress in critical bulk drugs remained uneven, according to an impact assessment published by NITI Aayog in partnership with IIM Ahmedabad.

According to the report, the pharmaceuticals drugs scheme, which had an outlay of `15,000 crore, has shown positive outcomes in attracting investment, production, employment and exports. Though the bulk drugs scheme, with a `6,940-crore outlay, enabled first-time domestic manufacturing of 191 bulk drugs, NITI Aayog said it has produced uneven but encouraging results.

The assessment found that large pharmaceutical firms recorded the strongest performance, aided by scale and global market integration. Mid-sized firms improved steadily, though MSMEs faced uneven outcomes, particularly in exports, because of constraints related to scale and market access. Investment has consistently exceeded targets, while production and employment have grown significantly.

For bulk drugs, chemical synthesis-based key starting materials, drug intermediates and active pharmaceutical ingredients have emerged as the strongest performers. Segment I drugs, which include key fermentation-based starting materials and drug intermediates, recorded a late but sharp production scale-up. Segment II drugs — niche fermentation-based starting materials, intermediates and APIs — grew gradually from a low base. However, segment III drugs, which include key chemical synthesis-based starting materials and intermediates, remained vulnerable across indicators.

These findings are especially relevant to Hyderabad, which is a major hub of pharmaceutical and life-sciences companies, research institutions and manufacturing units. Industry representatives said the city’s Active Pharmaceutical Ingredients (API), formulation and specialty-chemical base could benefit from greater domestic value addition and reduced dependence on imported inputs.

“The PLI results confirm that Hyderabad’s pharma ecosystem is well placed to capture the next phase of India’s manufacturing growth. But companies must invest in green chemistry, continuous manufacturing and high-value APIs, rather than compete only on volumes,” said Dr. Ramchander Sharma, a Hyderabad-based pharma industry expert.

Disclaimer : This story is auto aggregated by a computer programme and has not been created or edited by DOWNTHENEWS. Publisher: deccanchronicle.com